Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab

被引：14
|
作者：
Tejpar, S.
Bokemeyer, C.
Celik, I.
Schlichting, M.
Sartorius, U.
Van Cutsem, E.
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] Merck KGaA, Darmstadt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3511
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
    Nakamura, Masato
    Aoyama, Toru
    Ishibashi, Keiichiro
    Tsuji, Akihito
    Takinishi, Yasutaka
    Shindo, Yoshiaki
    Sakamoto, Junichi
    Oba, Koji
    Mishima, Hideyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 29 - 36
  • [22] Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study
    Tejpar, Sabine
    Lenz, Heinz-Josef
    Koehne, Claus-Henning
    Heinemann, Volker
    Ciardiello, Fortunato
    Esser, Regina
    Beier, Frank
    Stroh, Christopher
    Duecker, Klaus
    Bokemeyer, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [23] First-line therapy with cetuximab followed by cetuximab plus folfiri in patients with metastatic colorectal cancer: KRAS mutation status correlates with clinical outcome
    Martinelli, E.
    Macarulia, T.
    Vega-Villegas, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Ramos, F.
    Rivera, F.
    Stroh, C.
    Nippgen, J.
    Cervantes, A.
    Baselga, J.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [24] Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
    Masato Nakamura
    Toru Aoyama
    Keiichiro Ishibashi
    Akihito Tsuji
    Yasutaka Takinishi
    Yoshiaki Shindo
    Junichi Sakamoto
    Koji Oba
    Hideyuki Mishima
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 29 - 36
  • [25] Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: Effect of KRAS mutation on treatment efficacy in Taiwanese patients
    Chen, M. C.
    Chiang, F. F.
    Wang, H. M.
    NEOPLASMA, 2013, 60 (05) : 561 - 567
  • [26] The impact of toxicity and efficacy on quality of life in KRAS wild-type metastatic colorectal cancer patients treated with first-line chemotherapy plus cetuximab
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Von Hohnhorst, P.
    Esser, R.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S518 - S518
  • [27] KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy
    Cunha Pereira, T.
    Salgueiro, F.
    Monteiro, A.
    Felix Soares, R.
    Macedo, F.
    Jacinto, P.
    Paulo, J.
    Bonito, N.
    Marques, M.
    Ribeiro, J.
    Sousa, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S163 - S164
  • [28] ANALYSIS OF MOLECULAR ALTERATIONS FOR PREDICTING CLINICAL BENEFIT TO CETUXIMAB PLUS CHEMOTHERAPY IN FIRST-LINE METASTATIC COLORECTAL CANCER (MCRC)
    Javier, Sastre
    Patricia, Llovet
    Julian, Sanz
    Inmaculada, Bando
    Milagros, Ferrer
    Alfonso Pilar, Garcia
    Olga, Donnay
    Alfredo, Carrato
    Ana, Jimenez-Gordo
    Enrique, Aranda
    Ana, Leon
    Cristina, Gravalos
    Juan Carlos, Camara
    Jaime, Feliu
    Beatriz, Sanchiz
    Trinidad, Caldes
    Eduardo, Diaz-Rubio
    ANNALS OF ONCOLOGY, 2014, 25
  • [29] Influence of BRAF mutations and RAC1b/RAC1 mRNA ratio or protein expression on outcome in patients with metastatic Colorectal Cancer (mCRC) treated with first-line chemotherapy
    Cuatrecasas, M.
    Alonso-Espinaco, V.
    Jares, P.
    Horndler, C.
    Castells, A.
    Lozano, J. J.
    Maurel, J.
    VIRCHOWS ARCHIV, 2012, 461 : S13 - S13
  • [30] Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab plus Irinotecan
    Bando, Hideaki
    Yoshino, Takayuki
    Yuki, Satoshi
    Shinozaki, Eiji
    Nishina, Tomohiro
    Kadowaki, Shigenori
    Yamazaki, Kentaro
    Kajiura, Shinya
    Tsuchihara, Katsuya
    Fujii, Satoshi
    Yamanaka, Takeharu
    Ohtsu, Atsushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (12) : 1146 - 1151
12345